Clinical trial
An Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
Name
IMC-002-K102
Description
This is an Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients with Advanced Cancer Failed to Standard Therapy
Trial arms
Trial start
2022-05-10
Estimated PCD
2025-06-30
Trial end
2026-12-31
Status
Recruiting
Phase
Early phase I
Treatment
IMC-002
IMC-002 blocks the interaction between CD47 and SIRPα.
Arms:
IMC-002
Size
49
Primary endpoint
Incidence of Dose-Limiting Toxicities (DLTs)
21 days
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
through study completion, an average of 1 year
Eligibility criteria
Inclusion Criteria:
1. Signed ICF
2. Histologically or cytologically proven metastatic or locally advanced solid tumors
3. Subject must have at least 1 measurable lesion by RECIST 1.1.
4. Availability of tumor archival material or fresh biopsies
5. Adequate hematologic function, hepatic function, and renal function
6. Agree to use effective contraception
7. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
Exclusion Criteria:
1. Treatment with nonpermitted drugs
2. Prior treatment with a CD47 or SIRPα targeting agent
3. Concurrent anticancer treatments
4. Major surgery or significant traumatic injury prior to Screening or planned major surgery during the study period
5. Previous malignant disease other than the target malignancy for this study
6. Active infection requiring systemic therapy before Day 1
7. Any active autoimmune disease, or history of autoimmune disease
8. Any psychiatric or cognitive condition
9. Known severe hypersensitivity reaction
10. Pregnant or lactating
11. Currently enrolled in another clinical study
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'Part 1: Dose Escalation Part 2: Expansion cohort', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 49, 'type': 'ESTIMATED'}}
Updated at
2024-04-12
1 organization
1 product
1 abstract
1 indication
Product
IMC-002Indication
Advanced CancerOrganization
ImmuneOncia TherapeuticsAbstract
Updated safety, efficacy, pharmacokinetics, and biomarkers from the phase 1 study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors.Org: College of Pharmacy, Chungnam National University,